Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mimica, Ninoslav
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia	Completed	3	464	Europe, US, RoW	SEP-363856 75mg, SEP-363856 100mg, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	06/23	06/23
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Recruiting	3	375	Europe, US, RoW	Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo	Suven Life Sciences Limited, Suven Life Sciences Ltd	Agitation, Alzheimer's Type Dementia	01/25	01/25